354 related articles for article (PubMed ID: 25091027)
21. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
22. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
23. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
24. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
[TBL] [Abstract][Full Text] [Related]
25. Treatment of chronic hepatitis C in southern Taiwan.
Chuang WL; Yu ML; Dai CY; Chang WY
Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
[TBL] [Abstract][Full Text] [Related]
26. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
Poynard T; Colombo M; Bruix J; Schiff E; Terg R; Flamm S; Moreno-Otero R; Carrilho F; Schmidt W; Berg T; McGarrity T; Heathcote EJ; Gonçales F; Diago M; Craxi A; Silva M; Bedossa P; Mukhopadhyay P; Griffel L; Burroughs M; Brass C; Albrecht J;
Gastroenterology; 2009 May; 136(5):1618-28.e2. PubMed ID: 19208349
[TBL] [Abstract][Full Text] [Related]
27. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
[TBL] [Abstract][Full Text] [Related]
28. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
29. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
30. [Impact of age and sex on virologic responses of peginterferon alfa-2a and ribavirin treatment in chronic hepatitis C].
Yu JW; Sun LJ; Kang P; Zhao YH; Yan BZ; Zhu PF
Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1002-7. PubMed ID: 22333166
[TBL] [Abstract][Full Text] [Related]
31. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Hung CH; Lee CM; Lu SN; Wang JH; Hu TH; Tung HD; Chen CH; Chen WJ; Changchien CS
J Viral Hepat; 2006 Jun; 13(6):409-14. PubMed ID: 16842444
[TBL] [Abstract][Full Text] [Related]
32. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
[TBL] [Abstract][Full Text] [Related]
33. Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy.
Narita Y; Genda T; Tsuzura H; Sato S; Kanemitsu Y; Ishikawa S; Kikuchi T; Hirano K; Iijima K; Wada R; Ichida T
J Gastroenterol Hepatol; 2014 Jan; 29(1):137-43. PubMed ID: 24117602
[TBL] [Abstract][Full Text] [Related]
34. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.
Fried MW; Hadziyannis SJ; Shiffman ML; Messinger D; Zeuzem S
J Hepatol; 2011 Jul; 55(1):69-75. PubMed ID: 21145856
[TBL] [Abstract][Full Text] [Related]
35. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
Hasan F; Asker H; Al-Khaldi J; Siddique I; Al-Ajmi M; Owaid S; Varghese R; Al-Nakib B
Am J Gastroenterol; 2004 Sep; 99(9):1733-7. PubMed ID: 15330911
[TBL] [Abstract][Full Text] [Related]
36. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
[TBL] [Abstract][Full Text] [Related]
37. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
Swain MG; Lai MY; Shiffman ML; Cooksley WG; Zeuzem S; Dieterich DT; Abergel A; Pessôa MG; Lin A; Tietz A; Connell EV; Diago M
Gastroenterology; 2010 Nov; 139(5):1593-601. PubMed ID: 20637202
[TBL] [Abstract][Full Text] [Related]
38. Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C.
Coban S; Idilman R; Erden E; Tüzün A
Hepatogastroenterology; 2011; 58(109):1301-6. PubMed ID: 21937399
[TBL] [Abstract][Full Text] [Related]
39. Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: a single United Arab Emirates center experience.
Giguere A; Anas A; Nasser T; Hassan MH; Ahmed U; Beejay N; Nouh M; Khalowf M; Saleh A; Khan A; Attia M; El-Azab G
Eur J Intern Med; 2011 Dec; 22(6):582-6. PubMed ID: 22075284
[TBL] [Abstract][Full Text] [Related]
40. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
Shiffman ML; Ghany MG; Morgan TR; Wright EC; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Gretch DR
Gastroenterology; 2007 Jan; 132(1):103-12. PubMed ID: 17241864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
